P Minneci

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Increasing the efficacy of anti-inflammatory agents used in the treatment of sepsis
    P Minneci
    Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Eur J Clin Microbiol Infect Dis 22:1-9. 2003
  2. ncbi Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose
    Peter C Minneci
    Clinical Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann Intern Med 141:47-56. 2004
  3. ncbi Differing effects of epinephrine, norepinephrine, and vasopressin on survival in a canine model of septic shock
    Peter C Minneci
    Critical Care Medicine Department, National Institutes of Health, 10 Center Dr, Bldg 10, Rm 7D43, Bethesda, MD 20892, USA
    Am J Physiol Heart Circ Physiol 287:H2545-54. 2004
  4. ncbi A canine model of septic shock: balancing animal welfare and scientific relevance
    Peter C Minneci
    Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Physiol Heart Circ Physiol 293:H2487-500. 2007
  5. ncbi Effects of intra-aortic balloon counterpulsation in a model of septic shock
    Steven B Solomon
    Department of Critical Care Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Crit Care Med 37:7-18. 2009
  6. ncbi Novel therapies for sepsis: a review
    Katherine J Deans
    Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    J Trauma 58:867-74. 2005
  7. ncbi Defining the standard of care in randomized controlled trials of titrated therapies
    Katherine J Deans
    Critical Care Medicine Department, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Crit Care 10:579-82. 2004
  8. ncbi Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness
    Michael Haley
    Critical Care Medicine Department, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Infect Dis 17:205-11. 2004
  9. ncbi Practice misalignments in randomized controlled trials: Identification, impact, and potential solutions
    Katherine J Deans
    Department of Surgery, The Children s Institute for Surgical Science, The Children s Hospital of Philadelphia, Abramson Research Center, Rm 1116, 34th St and Civic Center Blvd, Philadelphia, PA 19104, USA
    Anesth Analg 111:444-50. 2010
  10. ncbi Recombinant human activated protein C in sepsis: assessing its clinical use
    Michael Haley
    Critical Care Medicine Department, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Med Sci 328:215-9. 2004

Detail Information

Publications20

  1. ncbi Increasing the efficacy of anti-inflammatory agents used in the treatment of sepsis
    P Minneci
    Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Eur J Clin Microbiol Infect Dis 22:1-9. 2003
    ..Developing better methods to define high-risk septic populations for treatment with anti-inflammatory agents will increase the efficacy of this therapeutic approach and minimize its potential for harm...
  2. ncbi Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose
    Peter C Minneci
    Clinical Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann Intern Med 141:47-56. 2004
    ..Previous meta-analyses demonstrated that high-dose glucocorticoids were not beneficial in sepsis. Recently, lower-dose glucocorticoids have been studied...
  3. ncbi Differing effects of epinephrine, norepinephrine, and vasopressin on survival in a canine model of septic shock
    Peter C Minneci
    Critical Care Medicine Department, National Institutes of Health, 10 Center Dr, Bldg 10, Rm 7D43, Bethesda, MD 20892, USA
    Am J Physiol Heart Circ Physiol 287:H2545-54. 2004
    ..In the ranges studied, norepinephrine and vasopressin have more favorable risk-benefit profiles than epinephrine during sepsis...
  4. ncbi A canine model of septic shock: balancing animal welfare and scientific relevance
    Peter C Minneci
    Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Physiol Heart Circ Physiol 293:H2487-500. 2007
    ..The integration into this model of both specific and supportive titrated therapies routinely used in septic patients may provide a more realistic setting to evaluate therapies for sepsis...
  5. ncbi Effects of intra-aortic balloon counterpulsation in a model of septic shock
    Steven B Solomon
    Department of Critical Care Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Crit Care Med 37:7-18. 2009
    ..Fluid refractory septic shock can develop into a hypodynamic cardiovascular state in both children and adults. Despite management of these patients with empirical inotropic therapy (with or without a vasodilator), mortality remains high...
  6. ncbi Novel therapies for sepsis: a review
    Katherine J Deans
    Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    J Trauma 58:867-74. 2005
    ..CONCLUSION: Trials of agents directed at altering the host's response during sepsis have had variable results, and it appears that several different factors may alter the efficacy of these agents...
  7. ncbi Defining the standard of care in randomized controlled trials of titrated therapies
    Katherine J Deans
    Critical Care Medicine Department, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Crit Care 10:579-82. 2004
    ..To discuss the appropriate standard of care in randomized controlled trials of titrated therapies in critically ill patients...
  8. ncbi Activated protein C in sepsis: emerging insights regarding its mechanism of action and clinical effectiveness
    Michael Haley
    Critical Care Medicine Department, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Opin Infect Dis 17:205-11. 2004
    ....
  9. ncbi Practice misalignments in randomized controlled trials: Identification, impact, and potential solutions
    Katherine J Deans
    Department of Surgery, The Children s Institute for Surgical Science, The Children s Hospital of Philadelphia, Abramson Research Center, Rm 1116, 34th St and Civic Center Blvd, Philadelphia, PA 19104, USA
    Anesth Analg 111:444-50. 2010
    ..Because these designs may limit the feasibility of a clinical trial, a thorough characterization of usual care is necessary to determine whether one of these designs should be used to protect patient safety...
  10. ncbi Recombinant human activated protein C in sepsis: assessing its clinical use
    Michael Haley
    Critical Care Medicine Department, Warren G Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    Am J Med Sci 328:215-9. 2004
    ..Further phase IV testing will be required to confirm such possibilities...
  11. ncbi Randomization in clinical trials of titrated therapies: unintended consequences of using fixed treatment protocols
    Katherine J Deans
    Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Crit Care Med 35:1509-16. 2007
    ..The practice misalignments created by such designs may have unintended effects on trial results and safety...
  12. ncbi Nitrite reductase activity of hemoglobin as a systemic nitric oxide generator mechanism to detoxify plasma hemoglobin produced during hemolysis
    Peter C Minneci
    Department of Surgery, The Children s Institute for Surgical Science, The Children s Hospital of Philadelphia, PA, USA
    Am J Physiol Heart Circ Physiol 295:H743-54. 2008
    ..Nitrite infusions may promote NO generation from Hb while maintaining oxygen delivery; this effect could be harnessed to treat hemolytic conditions and to detoxify Hb-based blood substitutes...
  13. ncbi Impact of animal strain on gene expression in a rat model of acute cardiac rejection
    Katherine J Deans
    Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    BMC Genomics 10:280. 2009
    ..Using a rat heart transplant model and 2 different rat strains (Dark Agouti, and Brown Norway), microarrays were performed on native hearts, transplanted hearts, and peripheral blood mononuclear cells (PBMC)...
  14. ncbi Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin
    Peter C Minneci
    Critical Care Medicine Department, NIH, Bethesda, Maryland 20892, USA
    J Clin Invest 115:3409-17. 2005
    ....
  15. ncbi Substantiating the concerns about recombinant human activated protein C use in sepsis
    Katherine J Deans
    Crit Care Med 32:2542-3. 2004
  16. ncbi Mechanical ventilation in ARDS: One size does not fit all
    Katherine J Deans
    Crit Care Med 33:1141-3. 2005
  17. ncbi The efficacy of drotrecogin alfa depends on severity of illness
    Katherine J Deans
    Crit Care Med 32:2347. 2004
  18. ncbi Corticosteroids for septic shock
    Peter C Minneci
    Ann Intern Med 141:742-3. 2004
  19. ncbi Should we continue to target the platelet-activating factor pathway in septic patients?
    Peter C Minneci
    Crit Care Med 32:585-8. 2004
  20. ncbi Antithrombotic therapies for sepsis: a need for more studies
    Peter C Minneci
    Crit Care Med 34:538-41. 2006